Update of the MSKCC nomogram for metastatic progression and its role in active surveillance: the Italian TPCP cohort - Takeaways - MDSpire

Update of the MSKCC nomogram for metastatic progression and its role in active surveillance: the Italian TPCP cohort

  • By

  • Nicolas Destefanis

  • Daniela Zugna

  • Valentina Fiano

  • Renata Zelic

  • Michelangelo Fiorentino

  • Francesca Giunchi

  • Piero Fariselli

  • Mauro Giulio Papotti

  • Paola Cassoni

  • Marco Oderda

  • Paolo Gontero

  • Luca Lianas

  • Mauro Del Rio

  • Giuseppe Carlo Iorio

  • Umberto Ricardi

  • Olof Akre

  • Andreas Pettersson

  • Lorenzo Richiardi

  • May 13, 2026

  • 0 min

Share

  • 1

    The MSKCC nomogram outperformed the D’Amico and CAPRA models in predicting metastatic prostate cancer and overall mortality.

  • 2

    Using the MSKCC nomogram increased the proportion of patients eligible for active surveillance from 7.8% to 57.0%.

  • 3

    The study analyzed 891 prostate cancer patients diagnosed in Turin, Italy, between 2008 and 2013.

  • 4

    The primary outcome measured was the occurrence of metastatic prostate cancer within five years of diagnosis.

  • 5

    Implementing nomogram-based risk thresholds could enhance patient selection for active surveillance and improve shared decision-making.

Original Source(s)

Update of the MSKCC nomogram for metastatic progression and its role in active surveillance: the Italian TPCP cohort

  • by Nicolas Destefanis, Daniela Zugna, Valentina Fiano, Renata Zelic, Michelangelo Fiorentino, Francesca Giunchi, Piero Fariselli, Mauro Giulio Papotti, Paola Cassoni, Marco Oderda, Paolo Gontero, Luca Lianas, Mauro Del Rio, Giuseppe Carlo Iorio, Umberto Ricardi, Olof Akre, Andreas Pettersson, Lorenzo Richiardi

  • May 13, 2026

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms